Tharimmune Financials
| THAR Stock | 2.08 0.18 7.96% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.33 | 6.0309 |
|
|
The essential information of the day-to-day investment outlook for Tharimmune includes many different criteria found on its balance sheet. An individual investor should monitor Tharimmune's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tharimmune.
Net Income |
|
Tharimmune | Select Account or Indicator |
Understanding current and past Tharimmune Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tharimmune's financial statements are interrelated, with each one affecting the others. For example, an increase in Tharimmune's assets may result in an increase in income on the income statement.
Tharimmune Stock Summary
Tharimmune competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, Enliven Therapeutics, and Molecular Partners. Tharimmune is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 432705101 432705200 432705309 |
| Location | New Jersey; U.S.A |
| Business Address | 1200 Route 22 |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.tharimmune.com |
| Phone | 908 955 3140 |
Tharimmune Key Financial Ratios
| Return On Equity | -4.55 | ||||
| EBITDA | (9.3 M) | ||||
| Net Income | (9.32 M) | ||||
| Book Value Per Share | 2.35 X | ||||
| Market Capitalization | 3.36 M |
Tharimmune Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tharimmune's current stock value. Our valuation model uses many indicators to compare Tharimmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tharimmune competition to find correlations between indicators driving Tharimmune's intrinsic value. More Info.Tharimmune is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Tharimmune's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tharimmune by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tharimmune Systematic Risk
Tharimmune's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tharimmune volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Tharimmune correlated with the market. If Beta is less than 0 Tharimmune generally moves in the opposite direction as compared to the market. If Tharimmune Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tharimmune is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tharimmune is generally in the same direction as the market. If Beta > 1 Tharimmune moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tharimmune Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tharimmune's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tharimmune growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Tharimmune November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tharimmune help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tharimmune. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tharimmune based on widely used predictive technical indicators. In general, we focus on analyzing Tharimmune Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tharimmune's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 85.88 | |||
| Value At Risk | (10.70) | |||
| Potential Upside | 9.22 |
Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.